PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Novo Medi Sciences aims to reach millions nationwide and provide NEXIPOX PLUS vaccination against chickenpox to thousands of underprivileged girl children
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Subscribe To Our Newsletter & Stay Updated
